Skip to main content

Significant investments

Typically, building a strategic position begins by investing in a private company with development potential and expands at follow-on financing rounds as well as IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 31 December 2023

CHF
232
million
Shanghai Cathay Biotech
Swixx BioPharma
CHF
154
million
CHF
58
million
Harmony Biosciences
Neurelis
CHF
47
million
CHF
47
million
Fangzhou (Jianke)
Upstream Bio
CHF
31
million
ConnectRN
CHF
31
million